GLP-1 receptor agonists have attracted considerable interest in New Zealand over the past couple of years — partly driven by high-profile coverage overseas, and partly because the clinical results genuinely are remarkable by the standards of weight management medicine.

But access is not unlimited, and not everyone who wants these medications will qualify for them. Understanding the criteria and the process helps set realistic expectations.

What Are GLP-1 Medications?

GLP-1 stands for glucagon-like peptide-1. Medications in this class mimic a hormone that the gut naturally releases in response to food. They act on receptors in the brain that regulate appetite, slow the rate at which the stomach empties, and influence blood sugar regulation.

Semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda) are among the most widely used GLP-1 agents in New Zealand. Tirzepatide (Mounjaro), which targets GLP-1 and GIP receptors, has also become available.

Who Typically Qualifies?

Prescribing criteria for weight loss medication nz generally centre on body mass index (BMI), the presence of weight-related health conditions, and previous attempts at lifestyle-based weight management. While criteria vary by prescriber and platform, typical considerations include:

• BMI of 30 or above (obesity)
• BMI of 27 or above with at least one weight-related condition such as type 2 diabetes, hypertension, sleep apnoea, or dyslipidaemia
• A history of attempting dietary and lifestyle interventions without sufficient results
• No contraindications to the specific medication (certain thyroid conditions, pregnancy, and some gastrointestinal conditions preclude use)

How to Access GLP-1 Medications in New Zealand

The process starts with a medical consultation. Your doctor will review your health history, current medications, and any relevant investigations before determining whether GLP-1 treatment is appropriate.

This can be done through your regular GP or through a telehealth provider who offers weight management services. The consultation will typically include a review of your BMI, relevant lab results (blood glucose, lipids, kidney function), and a discussion of what to expect from treatment.

What Does Treatment Look Like?

GLP-1 medications are administered by injection — typically weekly for semaglutide and tirzepatide. Most patients start on a low dose, which is gradually increased to minimise side effects (the most common of which are nausea, constipation, and other gastrointestinal symptoms).

Treatment is intended to be used alongside lifestyle modification. The medications reduce appetite, which makes it easier to reduce caloric intake, but sustainable results are generally associated with patients who also make meaningful changes to diet and physical activity.

Cost Considerations

For most people accessing GLP-1 medications for weight management, the cost is private. Monthly costs can be significant, which is worth factoring into any decision. Some providers offer structured programmes that include ongoing monitoring as part of the package.